Evidence map›Paper›PMID 40091002›Full record

ArticleDigestive diseases and sciences2025

Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study.

Lisa M A van Lierop, Larissa Albino, Ryan Rosentreter, Pepijn W A Thomas, Cathy Lu, Jesse Siffledeen, Karen I Kroeker, Christopher Ma, Farhad Peerani, Brendan P Halloran and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lisa M A van LieropDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada. lvanlier@ualberta.ca.
Larissa AlbinoDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Ryan RosentreterDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Pepijn W A ThomasDepartment of Gastroenterology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cathy LuDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Jesse SiffledeenDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Karen I KroekerDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Christopher MaDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Farhad PeeraniDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Brendan P HalloranDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Daniel C BaumgartDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Levinus A DielemanDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Lillian DuDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Frank HoentjenDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.
Karen WongDivision of Gastroenterology, Department of Medicine, University of Alberta, 130 University Campus NW, Edmonton, AB, T6G 2X8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUstekinumab dose escalation (DE) may be an effective strategy to recapture clinical response in patients with ulcerative colitis (UC). The aim of this study was to assess the real-world long-term effectiveness and safety outcomes following ustekinumab DE in patients with moderate-to-severe UC.

methodsThis multicenter retrospective cohort study included patients with moderate-to-severe UC who received at least one IV induction ustekinumab dose between January 2016 and November 2021. We compared ustekinumab DE to no DE, examining clinical, biochemical, and endoscopic disease outcomes. The primary endpoint was corticosteroid-free clinical remission (partial Mayo score ≤ 2 without systemic corticosteroids) at the end of follow-up. Cox proportional hazards regression analysis was performed for factors associated with time to DE, and a Kaplan-Meier plot was created for visualizing drug persistence probabilities.

resultsWe enrolled 121 patients. Eighty-one patients (67%) underwent DE during a median follow-up of 141 weeks. Corticosteroid-free clinical remission at the end of follow-up was achieved for 53.1% (DE group) and 57.5% (non-DE group). Discontinuation rates were 54.3% (DE group) versus 42.5% (non-DE group), mainly due to a lack of effectiveness. Two patients discontinued ustekinumab for adverse events. Ustekinumab persistence probability after 2 years was 40% (DE group) versus 79% (non-DE group).

conclusionsOur results indicate that DE is a commonly used method for optimizing ustekinumab treatment in moderate-to-severe UC. While DE appears safe, effectiveness and drug persistence beyond 2 years are limited.

Indexed as

Colitis, UlcerativeUstekinumabAdultAgedDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment OutcomeUstekinumabBiologicDose escalationInflammatory bowel diseaseUlcerative colitisUstekinumab

Identifiers

PMID40091002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.